Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease

AAPS Journal

Volumn 11, Issue 3, 2009, Pages 456-464

  Bhattaram, Venkatesh Atul ^a   Siddiqui, Ohidul ^b   Kapcala, Leonard P ^b   Gobburu, Jogarao V S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Delayed start; Disease modification; Neuroprotection; Parkinson's disease; Randomized start

Indexed keywords

ANTIPARKINSON AGENT; PLACEBO;

ARTICLE; DISEASE COURSE; DISEASE SIMULATION; DRUG EFFICACY; DRUG WITHDRAWAL; FALSE POSITIVE RESULT; MATHEMATICAL MODEL; PARKINSON DISEASE; STATISTICAL ANALYSIS; UNIFIED PARKINSON DISEASE RATING SCALE;

ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; PARKINSON DISEASE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 73349136256     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9123-2     Document Type: Article

References (23)

1. P Leber 1997 Slowing the progression of Alzheimer disease: methodological issues Alzheimer Dis Assoc Disord 11 5 S10 S21 9348423
2. RB Mani 2004 The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint Stat Med 23 2 305 314 14716731 10.1002/sim.1718 (Pubitemid 38100643)
3. CE Clarke 2004 A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs? Mov Disord 19 5 491 498 15133811 10.1002/mds.20057
4. Parkinson Study Group 2004 A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease Arch Neurol 61 4 561 566 10.1001/archneur.61.4.561 (Pubitemid 38923747)
5. PL Chan NH Holford 2001 Drug treatment effects on disease progression Annu Rev Pharmacol Toxicol 41 625 659 11264471 10.1146/annurev.pharmtox.41.1.625 1:CAS:528:DC%2BD3MXjsVaqt7s%3D (Pubitemid 32385901)
6. P Guimaraes K Kieburtz CG Goetz, et al. 2005 Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials Clin Trials 2 6 509 518 16422311 10.1191/1740774505cn125oa (Pubitemid 43075658)
7. DB Rubin 1976 Inference and missing data Biometrika 63 581 592 10.1093/biomet/63.3.581
8. Little RJA, Rubin DB. Statistical analysis with missing data. New York: Wiley; 1987.
9. The NINDS NET-PD Investigators 2006 A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease Neurology 66 5 664 671 10.1212/01.wnl.0000201252.57661.e1 (Pubitemid 43739819)
10. CW Shults D Oakes K Kieburtz, et al. 2002 Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline Arch Neurol 59 10 1541 1550 12374491 10.1001/archneur.59.10.1541
11. The NINDS NET-PD Investigators 2007 A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease Neurology 68 1 20 28 10.1212/01.wnl.0000250355.28474.8e (Pubitemid 46058546)
12. NH Holford PL Chan JG Nutt, et al. 2006 Disease progression and pharmacodynamics in Parkinson disease-evidence for functional protection with levodopa and other treatments J Pharmacokinet Pharmacodyn 33 281 311 16625427 10.1007/s10928-006-9012-6 1:CAS:528:DC%2BD28Xms1Oisr0%3D (Pubitemid 44020383)
13. RL Watts J Jankovic C Waters, et al. 2007 Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease Neurology 68 4 272 276 17202432 10.1212/01.wnl.0000252355.79284.22 1:CAS:528:DC%2BD2sXlt12msg%3D%3D (Pubitemid 46148338)
14. AD Korczyn ER Brunt JP Larsen, et al. 1999 A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group Neurology 53 2 364 370 10430427 1:CAS:528:DyaK1MXltVKmtbs%3D
15. CW Olanow K Kieburtz M Stern, et al. 2004 Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease Arch Neurol 61 10 1563 1568 15477510 10.1001/archneur.61.10. 1563 1:STN:280:DC%2BD2crgslajsQ%3D%3D (Pubitemid 39350267)
16. JP Larsen J Boas JE Erdal 1999 Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group Eur J Neurol 6 5 539 547 10457386 10.1046/j.1468-1331.1999.650539.x 1:STN:280:DyaK1MzovVWnug%3D%3D
17. Parkinson Study Group 2002 A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study Arch Neurol 59 12 1937 1943 10.1001/archneur.59.12.1937 (Pubitemid 35424653)
18. Parkinson Study Group 2000 Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group JAMA 284 15 1931 1938 10.1001/jama.284.15.1931
19. S Fahn D Oakes I Shoulson, et al. 2004 Levodopa and the progression of Parkinson's disease N Engl J Med 351 24 2498 2508 15590952 10.1056/NEJMoa033447 1:CAS:528:DC%2BD2cXhtVGksbnE (Pubitemid 39603163)
20. S Palhagen E Heinonen J Hagglund, et al. 2006 Selegiline slows the progression of the symptoms of Parkinson disease Neurology 66 8 1200 1206 16540603 10.1212/01.wnl.0000204007.46190.54 1:STN:280:DC%2BD283ivFSgtQ%3D%3D (Pubitemid 43739704)
21. PL Chan JG Nutt NH Holford 2004 Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease J Pharmacokinet Pharmacodyn 31 3 243 268 15518246 10.1023/B:JOPA.0000039566.75368.59 1:CAS:528:DC%2BD2cXntVKru7o%3D (Pubitemid 39200528)
22. Ploeger BA, Holford NH. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis. Pharm Stat 2008, in press.
23. Hendrix SB. AAPS workshop on demonstrating disease-modifying effects for the treatment of Parkinson's disease: drug development and regulatory issues, Arlington, VA; 2008